New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Acute Cerebrovascular Episodes in Systemic Lupus Erythematosus
Quart J Med 293:739-750, Eustace,S.,et al, 1991
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
10 Most Commonly Asked Questions About Which Antiplatelet Agent to Prescribe
The Neurologist 9:318-322, Adams,H.P. Jr., 2003
Treatment of End Stage Dilated Cardiomyopathy
Br Heart J 72:S52-S56, O'Connell,J.B.,et al, 1996
Predictors of Thromboembolism in Atrial Fibrillation:I. Clinical Features of patients at Risk
The Stroke Prevention in A Fib Investigators, Ann Int Med 116:1-51992., , 1992
Superior Sagittal Sinus Thrombosis
Arch Neurol 34:2, Gettelfinger,D.M.,et al, 1977